Uperio 100mg (Sacubitril/Valsartan) 28 tablets in Kenya

UPERIO 100MG tablets come in a pack of 28 tabs. Each tablet contains Sacubitril and Valsartan Sodium Hydrate. This medicine combines two distinct drugs. It aims to reduce the risk of death and hospitalizations in people with long-lasting heart failure. Doctors usually prescribe it along with other heart failure medications. UPERIO 100MG is available only by prescription.

Unpacking the Formulation: Key Components and Their Mechanism

Uperio combines Sacubitril and Valsartan. These two active ingredients work together to improve heart function in distinct ways.

• Sacubitril (as part of Sacubitril Valsartan Sodium Hydrate):
  • Class: Neprilysin Inhibitor.
  • Mechanism of Action: Sacubitril is a prodrug. The body converts it into an active metabolite (LBQ657). This active metabolite inhibits neprilysin. Neprilysin is an enzyme that breaks down natural diuretic and vasodilating peptides in the body. By inhibiting neprilysin, sacubitril increases levels of these beneficial peptides. These peptides include natriuretic peptides (e.g., BNP, ANP) and bradykinin. Increased levels of these peptides lead to vasodilation (widening of blood vessels), increased sodium and water excretion (diuresis and natriuresis), and reduced cardiac remodeling. These actions reduce the strain on the heart.
• Valsartan (as part of Sacubitril Valsartan Sodium Hydrate):
  • Class: Angiotensin II Receptor Blocker (ARB).
  • Mechanism of Action: Valsartan blocks the effects of angiotensin II. Angiotensin II is a powerful hormone. It causes blood vessels to constrict and promotes fluid retention. By blocking angiotensin II receptors, valsartan relaxes blood vessels, lowers blood pressure, and reduces the workload on the heart. It also helps prevent cardiac remodeling and fibrosis.

The combination of sacubitril and valsartan (an Angiotensin Receptor-Neprilysin Inhibitor or ARNI) provides a dual mechanism. It enhances the protective neurohormonal systems (via neprilysin inhibition) and simultaneously suppresses the harmful ones (via angiotensin receptor blockade). This comprehensive approach significantly benefits heart failure patients.

Addressing Health Concerns and User Needs

Uperio 100mg specifically addresses the progressive nature of chronic heart failure. It aims to improve patient outcomes.

• Reduced Mortality and Hospitalizations: Uperio significantly reduces the risk of cardiovascular death and hospitalizations for worsening heart failure. This is its primary benefit.
• Improved Heart Function: It helps the heart pump blood more efficiently by relaxing blood vessels and reducing fluid overload.
• Symptom Management: Patients may experience improved symptoms of heart failure, such as shortness of breath and fatigue.
• Better Quality of Life: By mitigating heart failure progression, it can improve the overall quality of life for affected individuals.

Identifying Indications for Use

UPERIO 100MG (Sacubitril Valsartan Sodium Hydrate) is a prescription-only medication. Doctors indicate it for:

• Chronic Heart Failure with Reduced Ejection Fraction (HFrEF): It is specifically for adult patients with long-lasting heart failure where the heart’s pumping ability is weakened (ejection fraction below normal).
• Reduction of Cardiovascular Death and Hospitalization: Its main use is to lower these risks in the target patient population.
• Used with Other Heart Failure Therapies: Doctors typically prescribe it as part of a comprehensive treatment regimen for heart failure.

Primary Uses

The primary uses of UPERIO 100MG include:

• Lowering the risk of death from cardiovascular causes in heart failure patients.
• Reducing hospital admissions due to worsening heart failure.
• Improving the heart’s pumping efficiency and overall function.

Understanding Potential Side Effects and Critical Precautions

While Uperio 100mg offers significant benefits for heart failure, patients should understand its potential side effects and necessary precautions.

Common Side Effects (Generally mild to moderate)

• Low blood pressure (Hypotension): This is the most common side effect. It can cause dizziness or lightheadedness, especially when standing up.
• Cough: A dry, persistent cough can occur.
• High potassium levels (Hyperkalemia): This can happen, especially in patients with kidney problems or those taking potassium-sparing diuretics. Symptoms may include muscle weakness or an irregular heartbeat (in severe cases).
• Kidney problems (Renal impairment): Changes in kidney function, including worsening kidney function, can occur.
• Dizziness or lightheadedness.
• Fatigue or weakness.
• Nausea, vomiting, or diarrhea.

Less Common but More Serious Side Effects (Requiring Immediate Medical Attention)

• Angioedema: This is a rare but serious allergic reaction. It causes swelling of the face, lips, tongue, or throat. This can lead to difficulty breathing or swallowing and requires immediate emergency medical attention. If you have a history of angioedema with ACE inhibitors or ARBs, you should not take Uperio.
• Severely low blood pressure: This can lead to fainting or shock.
• Very high potassium levels: This can cause life-threatening heart rhythm problems.

Critical Safety Warnings and Precautions for UPERIO 100MG (Sacubitril Valsartan)

UPERIO 100MG is a prescription-only medication. A qualified physician, ideally a cardiologist, MUST strictly supervise its use.

Contraindications and High-Risk Patients

• History of Angioedema: Do NOT use in patients with a history of angioedema related to previous ACE inhibitor or ARB therapy. The risk of recurrence is high and potentially life-threatening.
• Concomitant ACE Inhibitor Use: Do NOT use Uperio concurrently with an ACE inhibitor. Patients must discontinue ACE inhibitors at least 36 hours before starting Uperio.
• Aliskiren Co-administration: Avoid using Uperio with aliskiren (a direct renin inhibitor) in patients with diabetes or kidney impairment (eGFR < 60 mL/min/1.73 m2). This significantly increases the risk of hypotension, hyperkalemia, and kidney problems.
• Severe Liver Impairment: Avoid use in patients with severe liver impairment.
• Pregnancy: Uperio can cause fetal harm or death. Discontinue as soon as pregnancy is detected.
• Allergy: Avoid if allergic to sacubitril, valsartan, or any components of Uperio.

Administration and Monitoring

• Blood Pressure Monitoring: Regular blood pressure monitoring is essential, especially during initiation and dose titration.
• Kidney Function and Potassium Monitoring: Doctors must regularly monitor kidney function (serum creatinine) and potassium levels, especially in patients with pre-existing kidney disease, diabetes, or those taking potassium-sparing diuretics.
• Symptom Monitoring: Patients should report any symptoms of angioedema, severe dizziness, or significant changes in urine output immediately.
• Dose Titration: Treatment usually starts at a lower dose, which doctors gradually increase based on patient tolerance and response.
• Lactation: It is unknown if Uperio is excreted in human milk. Weigh the benefits of breastfeeding against the potential risks to the infant.

Drug Interactions

• ACE Inhibitors: (As mentioned above) Strictly contraindicated.
• Aliskiren: (As mentioned above) Strictly contraindicated in diabetes/renal impairment.
• Potassium-Sparing Diuretics (e.g., Spironolactone, Eplerenone), Potassium Supplements, Salt Substitutes Containing Potassium: These increase the risk of hyperkalemia. Use with caution and monitor potassium levels closely.
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs) including COX-2 Inhibitors: Concurrent use can worsen kidney function and reduce Uperio’s blood pressure-lowering effect. Monitor kidney function.
• Lithium: Uperio can increase lithium levels and toxicity. Monitor lithium levels.
• Other Antihypertensive Agents: Concurrent use with other blood pressure-lowering drugs may increase the risk of hypotension. Adjust doses as needed.
• Sildenafil (Viagra) / Tadalafil (Cialis): These can increase the blood pressure-lowering effect. Use with caution.

Recommended Dosage and Administration Guidelines

The dosage of UPERIO 100MG (Sacubitril Valsartan) is highly individualized. It depends on the patient’s existing heart failure treatment, kidney function, and blood pressure. Always follow your doctor’s precise prescription.

• General Administration:
  • Take the tablets orally.
  • Take them twice daily, generally in the morning and evening.
  • You can take them with or without food.
  • Swallow tablets whole. Do not crush or chew.
• Typical Starting Dose for Adults:
  • A common starting dose is 49mg/51mg (which is Uperio 100mg) orally twice daily. This means one tablet of Uperio 100mg twice a day.
  • For patients not currently taking an ACE inhibitor or ARB, or those on low doses, doctors might consider a lower starting dose (e.g., 24mg/26mg or Uperio 50mg, if available). This also applies to elderly patients (≥75 years) or those with lower baseline blood pressure or moderate kidney/liver impairment.
• Dose Titration:
  • The doctor will usually double the dose every 2 to 4 weeks, as tolerated by the patient.
  • The target maintenance dose is typically 97mg/103mg (which is Uperio 200mg) orally twice daily.
  • Dose adjustments depend on blood pressure, kidney function, and potassium levels.
• Conversion from ACE Inhibitor/ARB:
  • If switching from an ACE inhibitor, discontinue the ACE inhibitor for at least 36 hours before starting Uperio.
  • If switching from an ARB, a washout period is not typically needed, but the doctor will consider the patient’s specific ARB and clinical status.
• Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose.

Price in Kenya (Approximate)

As of Thursday, July 3, 2025, at 10:21 AM EAT, the approximate price for UPERIO 100MG | SACUBITRIL VALSARTAN SODIUM HYDRATE – 28 TABS in Kenya can range from Ksh 5,300 to Ksh 5,700 per pack.

Note: Prices for prescription medications like Uperio can vary between different pharmacies and online platforms in Kenya. Factors include supplier, specific brand formulation, and any prevailing duties or taxes. Always check with specific vendors for the most current pricing.

Conclusion

UPERIO 100MG (Sacubitril Valsartan Sodium Hydrate), provided in a 28-tablet pack, is a significant prescription medication in Kenya for managing chronic heart failure with reduced ejection fraction. This combination drug effectively reduces the risk of cardiovascular death and hospitalizations by enhancing beneficial peptides and blocking harmful neurohormonal pathways. Its use demands precise medical supervision due to potential side effects like hypotension, hyperkalemia, and the rare but serious risk of angioedema. Patients must strictly adhere to the prescribed dosing regimen and be mindful of crucial drug interactions, particularly avoiding concomitant use with ACE inhibitors. Regular monitoring of blood pressure, kidney function, and potassium levels is essential to ensure safe and effective treatment, ultimately aiming to improve outcomes and quality of life for individuals living with heart failure.